(Q73150366)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

A B Shanafelt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Y Lin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M C Shanafelt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

C P Forte

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

N Dubois-Stringfellow

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

C Carter

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

J A Gibbons

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

S L Cheng

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

K A Delaria

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

R Fleischer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

J M Greve

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

R Gundel

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

K Harris

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

R Kelly

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

B Koh

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Y Li

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

L Lantz

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

P Mak

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

L Neyer

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M J Plym

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

S Roczniak

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

D Serban

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

J Thrift

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

L Tsuchiyama

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M Wetzel

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M Wong

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

A Zolotorev

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 November 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

1197-1202

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 November 2019

cites work

1 reference

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

7 January 2021

Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease

1 reference

7 January 2021

A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. A Pediatric Oncology Group Study

1 reference

7 January 2021

Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study

1 reference

7 January 2021

Randomized Study of Interleukin 2 (IL-2) Alone vs IL-2 Plus Lymphokine-Activated Killer Cells for Treatment of Melanoma and Renal Cell Cancer

1 reference

7 January 2021

The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities

1 reference

7 January 2021

Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R

1 reference

7 January 2021

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

1 reference

7 January 2021

The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]

1 reference

7 January 2021

Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma

1 reference

7 January 2021

Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity

1 reference

7 January 2021

Unraveling the structure of IL-2

1 reference

7 January 2021

1 reference

7 January 2021

Interleukin 2 and its receptors: recent advances and new immunological functions

1 reference

7 January 2021

Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor

1 reference

7 January 2021

Structural and biologic properties of a human aspartic acid-126 interleukin-2 analog

1 reference

7 January 2021

ANALYSIS OF HUMAN IL-2/IL-2 RECEPTOR β CHAIN INTERACTIONS: MONOCLONAL ANTIBODY H2-8 AND NEW IL-2 MUTANTS DEFINE THE CRITICAL ROLE OF α HELIX-A OF IL-2

1 reference

7 January 2021

Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor

1 reference

7 January 2021

Interleukin 2 receptors

1 reference

7 January 2021

CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand

1 reference

7 January 2021

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding

1 reference

7 January 2021

Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells

1 reference

7 January 2021

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

7 January 2021

Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

1 reference

7 January 2021

Rapid and efficient site-specific mutagenesis without phenotypic selection

1 reference

7 January 2021

CLAMP: a biosensor kinetic data analysis program

1 reference

7 January 2021

Structure-activity relationships of recombinant human interleukin 2.

1 reference

7 January 2021

Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor

1 reference

7 January 2021

Identifiers

DOI

10.1038/81199

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11062441%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference